메뉴 건너뛰기




Volumn 9, Issue 5, 1999, Pages 461-468

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

Author keywords

Alendronate; Bisphosphonate; Bone mineral density; Fractures; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM;

EID: 0032896590     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004171     Document Type: Article
Times cited : (561)

References (20)
  • 1
    • 0029243810 scopus 로고
    • How many women have osteoporosis now?
    • Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7.
    • (1995) J Bone Miner Res , vol.10 , pp. 175-177
    • Melton L.J. III1
  • 4
    • 0026732689 scopus 로고
    • The prevention and treatment of osteoporosis
    • Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7.
    • (1992) N Engl J Med , vol.327 , pp. 620-627
    • Riggs, B.L.1    Melton L.J. III2
  • 5
    • 0028586042 scopus 로고
    • Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment
    • Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
    • (1994) J Clin Endocrinol Metab , vol.79 , pp. 1693-1700
    • Garnero, P.1    Shih, W.J.2    Gineyts, E.3    Karpf, D.B.4    Delmas, P.D.5
  • 6
    • 0027279616 scopus 로고
    • Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties
    • Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993;53:283-8.
    • (1993) Calcif Tissue Int , vol.53 , pp. 283-288
    • Guy, J.A.1    Shea, M.2    Peter, C.P.3    Morrissey, R.4    Hayes, W.C.5
  • 7
    • 0029875341 scopus 로고    scopus 로고
    • Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae
    • Balena R, Markatos A, Seedor JG, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J. Pharmacol Exp Ther 1996;276:277-83.
    • (1996) J. Pharmacol Exp Ther , vol.276 , pp. 277-283
    • Balena, R.1    Markatos, A.2    Seedor, J.G.3
  • 8
    • 0027139913 scopus 로고
    • The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhman primates
    • Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhman primates. J Clin Invest 1993;92:2577-86.
    • (1993) J Clin Invest , vol.92 , pp. 2577-2586
    • Balena, R.1    Toolan, B.C.2    Shea, M.3
  • 9
    • 0030868816 scopus 로고    scopus 로고
    • Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
    • Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
    • (1997) J Clin Invest , vol.100 , pp. 1475-1480
    • Chavassieux, P.M.1    Arlot, M.E.2    Reda, C.3    Wei, L.4    Yates, A.J.5    Meunier, P.J.6
  • 10
    • 0028851590 scopus 로고
    • Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
    • Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
    • (1995) N Engl J Med , vol.333 , pp. 1437-1443
    • Liberman, U.A.1    Weiss, S.R.2    Bröll, J.3
  • 11
    • 0027454352 scopus 로고
    • Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
    • Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
    • (1993) J Clin Endocrinol Metab , vol.77 , pp. 1046-1053
    • Garnero, P.1    Delmas, P.D.2
  • 12
    • 0026676875 scopus 로고
    • A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen crosslinked N-telopeptides in urine
    • Hanson DA, Weiss MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
    • (1992) J Bone Miner Res , vol.7 , pp. 1251-1258
    • Hanson, D.A.1    Weiss, M.A.E.2    Bollen, A.M.3    Maslan, S.H.4    Singer, F.R.5    Eyre, D.R.6
  • 13
    • 0029116697 scopus 로고
    • Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
    • Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
    • (1995) Am J Med , vol.99 , pp. 144-152
    • Chesnut C.H. III1    McClung, M.R.2    Ensrud, K.E.3
  • 14
    • 0028846051 scopus 로고
    • Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
    • Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
    • (1995) Bone , vol.17 , pp. 383-390
    • Adami, S.1    Passeri, M.2    Ortolani, S.3
  • 15
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 16
    • 0031006598 scopus 로고    scopus 로고
    • Prevention of non-vertebral fractures by alendronate: A meta-analysis
    • Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate: a meta-analysis. JAMA 1997;277:1159-64.
    • (1997) JAMA , vol.277 , pp. 1159-1164
    • Karpf, D.B.1    Shapiro, D.R.2    Seeman, E.3
  • 17
    • 0025765521 scopus 로고
    • Pre-existing fractures and bone mass predict vertebral fracture incidence in women
    • Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
    • (1991) Ann Intern Med , vol.114 , pp. 919-923
    • Ross, P.D.1    Davis, J.W.2    Epstein, R.S.3    Wasnich, R.D.4
  • 19
    • 0026630460 scopus 로고
    • Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
    • Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77.
    • (1992) Am J Epidemiol , vol.136 , pp. 165-177
    • Talley, N.J.1    Weaver, A.L.2    Zinsmeister, A.R.3    Melton L.J. III4
  • 20
    • 0010496839 scopus 로고    scopus 로고
    • Esophagitis associated with the use of alendronate
    • de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
    • (1996) N Engl J Med , vol.335 , pp. 1016-1021
    • De Groen, P.C.1    Lubbe, D.F.2    Hirsch, L.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.